HPV Specific Immune Lymphocytes (HPV-CTLs) in the Treatment of HPV

Inclusion Criteria12

• Written, informed consent obtained prior to any study-specific procedures.
• Evidence of HPV virus activation (viral DNA) or high risk of HPV infection.
• Not suitable for routine treatment or invalid to antiviral drugs.
• Patients with viral disease symptoms and confirmed by biopsy, regardless of the level of virus DNA.
• Age less than 75 years.
• Did not use Penicillin or β-lactam antibiotics, or the lowest dose of other antibiotics.
• Initial hematopoietic reconstitution: neutrophils (ANC) ≥ 1,000/mm\^3, platelet (PLT) ≥ 1,000/mm\^3.
• Proper renal and hepatic functions (ULN denotes "upper limit of normal range"): Creatinine ≤ 2*ULN, Bilirubin ≤ 2*ULN, SGOT/ SGPT ≤ 3*ULN.
• If HPV-CTL is not from the patient's own, then the provider of HPV-CTL needs to meet the following criteria:
• did not receive chemotherapy or radiotherapy within 4 weeks prior to blood collection, and did not take any steroids for the previous week, did not use Penicillin or β-lactam antibiotics, or the lowest dose of other antibiotics.
• white blood cells ≥ 3,500 / μl, lymphocytes ≥ 750 / μl.
• Human immunodeficiency virus (HIV) test was negative.